A Novel, Catecholamine Release-Inhibitory Peptide from Chromogranin A: Autocrine Control of Nicotinic Cholinergic-Stimulated Exocytosis
Sushil K. Mahata(University of California San Diego), Daniel T. O’Connor(Nova Southeastern University), Joseph P. Taulane(VA San Diego Healthcare System), Laurent Taupenot(University of California San Diego), Manjula Mahata(Uppsala University), Seung Hyun Yoo(University of California San Diego Medical Center), Haibo Wu, Caronotyn V. Livsey(University of California San Diego Medical Center), Vanita R. Aroda(Brigham and Women's Hospital), Murray Goodman(Advisory Board Company (United States)), Robert J. Parmer(Buck Institute for Research on Aging)
Cited by 20
Related Papers
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986
9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|850
The Chromogranin–Secretogranin Family
|New England Journal of Medicine|2003|820